ALSEN — Sensorion SA Share News
0.000.00%
Last trade - 00:00Brief: Sensorion Announces Oral Presentation At European Histamine Research Society
Brief: Sensorion: Positive DSMB Review, Continuation Of Phase 2 Clinical Trial For SENS-111
Brief: Sensorion FY IFRS Net Loss Widens To 12.4 Million Euros
Brief: Sensorion Issues EUR 4.7 Million Nominal Bond Issue
Brief: Sensorion To Present New Sens-401 Data At Aro 2019 Midwinter Meeting
Brief: Sensorion Announces Publication Of Positive SENS-401 Data
Brief: Sensorion Announces Positive Results From Seliforant Phase 2A Study
Brief: Sensorion Announces Publication In Hearing Research On Kinetics Of Prestin Blood Levels After Noise Trauma-Induced Hearing Loss
Brief: Sensorion Announces Completion Of Patient Enrollment
Brief: Sensorion Enters Into Exclusive Negotiations With Pasteur Institute
Brief: Sensorion Announces Presentation Of Sens-401 Poster At Society For Neuroscience
Brief: Sensorion: Cash Position Of EUR 8.8 Million As Of June 30
Brief: Sensorion Announces Publication Of Seliforant Phase 1 Study Data
Brief: Sensorion Receives European Authorization To Start Sens-401 Phase 2 Trial In Sudden Sensorineural Hearing Loss
Brief: Sensorion Initiates Safety Study Of Seliforant Vs Meclizine In Evoked Vestibular Imbalance
Brief: Sensorion Initiates Safety Study Of Seliforant Versus Meclizine In Evoked Vestibular Imbalance
Brief: Sensorion Shows Protective Effect Of Sens-401 In Hearing Loss Models
Brief: Sensorion Successfully Raises 8.65 Million Euros From Institutional Investors
Brief: Sensorion Launches Capital Increase Of Maximum 4.466.245 New Ordinary Shares